cGMP-Compliant, Validated Technology Enhances Biological Activity Enabling Clinical Delivery of Safe and Effective Cellular Therapeutics GAITHERSBURG, Md.–MaxCyte today announces the launch of the MaxCyte® GT™ Flow Transfection System to academic and clinical investigators. The MaxCyte® GT™ Flow Transfection System is a validated platform for optimizing the biological activity of cellular therapeutic products. The system, which […]
MUKILTEO, Wash., April 29, 2009 — CombiMatrix Corporation (NasdaqGM:CBMX – News) announced today that it has updated its Influenza-Detection Microarray to include sequence information of the latest strain of Swine Flu. The previous version of the Influenza-Detection Microarray already detected many strains of Swine Flu as well as the pathogenic Bird Flu. Today, within one […]
MUKILTEO, Wash., April 29, 2009 — CombiMatrix Corporation (NasdaqGM:CBMX – News) announced today that is has obtained commitments from a group of select investors to purchase up to $8.25 million of its common stock and warrants in a registered direct offering. Under the terms of the transaction, CombiMatrix will sell approximately 1.1 million units for […]
Seeplex® Diarrhea ACE Detection Tests for 14 Diarrhea Causing Pathogens ROCKVILLE, MD–(April 29, 2009) – Seegene today introduced the Seeplex® Diarrhea ACE Detection test that provides a novel and fast-acting multiplex PCR diagnostic technique to simultaneously verify a complex range of pathogens that cause diarrhea. Based on the company’s proprietary DPO (Dual Priming Oligo) technology, […]
SAN DIEGO–SEQUENOM, Inc. (NASDAQ: SQNM – News) announced today that the expected launch of its SEQureDx™ Down syndrome test is delayed, due to the discovery by company officials of employee mishandling of R&D test data and results. Accordingly the company is no longer relying on the previously announced R&D test data and results. SEQUENOM has […]
Viral sequence analysis suggests that two of the company’s screening tests identify currently spreading H1N1 subtype VENLO, The Netherlands–QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that two of its tests can be used to screen for the swine flu virus which increasingly affects humans in countries around the globe. Data analysis of the […]
Industry Veterans Will Introduce Breast Cancer Risk Stratifier to Help Physicians Determine Monitoring and Treatment Plans for Women with Intermediate Levels of Risk MOUNTAIN VIEW, Calif.–Perlegen Sciences, which develops genetic tests that correlate genetic variation to predisposition to disease and drug response, announced today that it has added key positions to its commercial team in […]
Expansion of Partnership Is A Direct Result of Recent Swine Flu Outbreak and RECEPTORS’ Recently Issued “Methods of Making Arrays and Artificial Receptors” Patent No. 7,504,364 and “Sensors Employing Combinatorial Artificial Receptors” Patent No. 7,469,076 Partners believe that unique intellectual property can lead to chemical isolation and detection of certain biological threats including, but not […]
– Test for Mycobacterium tuberculosis (TB) Expected to Highlight Broad On-Demand CE IVD Test Menu at Booth #611 SUNNYVALE, California, April 28 — Cepheid (Nasdaq: CPHD – News) today announced speaker and program highlights for its symposium, “Patient Management in the Era of Rapid Diagnostics,” which the company will host at the 19th European Congress […]
InforSense Accelerates and Automates Diagnostic Biomarker Discovery London, UK and Cambridge, MA, April, 27th, 2009 – InforSense Ltd., the leading provider of next generation business and scientific intelligence solutions, today announced that Celera Corporation, a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries, is using InforSense to […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
